AlzeCure gets Presentation Accepted on Disease-Modifying Effects of ACD856 at Alzheimer’s Conference
STOCKHOLM, SE / ACCESSWIRE / September 26, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
Clinical Trial
Rho to Lead U.S. Clinical Trials for Next Generation of COVID-19 Vaccines as Part of $5 Billion NextGen Initiative
RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 25, 2023 / The U.S. Department of Health and Human Services (HHS)...
Florence Healthcare Acquires VersaTrial to Accelerate Clinical Research Site Enablement
Florence Healthcare, the leading provider of Site Enablement Platforms for clinical trials, announced today that it has acquired VersaTrial, a...
Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary...
NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025Vancouver,...
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per shareSAN...
Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023
PALO ALTO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating...
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
Caren Deardorf Editas Medicine, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer.CAMBRIDGE,...
PharmAla Receives First Office Action for PharmAla-1 PCT Filing
PCT Examiner Finds Molecule to be both Novel and InventiveVANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech...
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed...
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
Further Supports TTX-MC138 Application in Brain CancerBOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA...
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were...
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDTPRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE)...
Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination
SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science company...
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),...
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming...
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP.This...
Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting
TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage...
InvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington
VANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biotechnology company building a...